Author Affiliation: Department of Medicine, Division of Digestive Disease and Nutrition, University of Massachusetts, Memorial Health Care, Worcester.
In the past decade, chronic hepatitis due to hepatitis C virus (HCV)
infection has emerged as the predominant liver disease in the United States.
While progression of chronic hepatitis C to cirrhosis may be slow, end-stage
liver disease due to HCV-associated cirrhosis is now the single most common
indication for liver transplantation, and HCV-associated cirrhosis is responsible
for the increasing incidence of hepatocellular carcinoma in this country.1 Direct costs of care for patients with progressive
disease are high, treatment is expensive, and the national economic burden
of hepatitis C has been projected to increase dramatically in the future.2 Fortunately, progress in antiviral treatment has been
steady and impressive.
Koff RS. Nonresponse to Interferon in Chronic Hepatitis CRe-treatment Redux. JAMA. 2001;285(2):212-214. doi:10.1001/jama.285.2.212